In the present study, we extended the above-mentioned findings to determine the broader extent by which RLX targeted the myofibroblast NLRP3 inflammasome to mediate its anti-fibrotic effects in HCMFs in vitro and in a murine model of cardiomyopathy in vivo. Here, NLRP3 is linked to cardiomyopathy.